Catherine Thieblemont
University of Paris
215 Papers
814 Citations
Catherine Thieblemont is an academic researcher from University of Paris. The author has contributed to research in topics: Lymphoma & Medicine. The author has an hindex of 45, co-authored 215 publications. Previous affiliations of Catherine Thieblemont include University of Lyon & Paris-Sorbonne University.
Chat about Author
Papers
T3 : A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Temsirolimus (Torisel™)-CHOP-Rituximab (T-R-CHOP), Temsirolimus (Torisel™)-FC-Rituximab (T-R-FC) and Temsirolimus (Torisel™)- DHA-Rituximab (T-R-DHA) for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL), a Lysa Study
Steven Le Gouill,Krimo Bouabdallah,Guillaume Cartron,Remy Gressin,Thierry Lamy,Bertrand Coiffier,Catherine Thieblemont,Corinne Haioun,Olivier Casasnovas,Emmanuel Gyan,Olivier Hermine +10 more
TL;DR: The T3 trial as discussed by the authors is a multicenter Phase IB dose escalation study that evaluates the safety, feasibility and efficacy of three Temsirolimus-based chemotherapy regimens.
1
499 Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma
Martin Dreyling,Pier Luigi Zinzani,Krimo Bouabdallah,D. Bron,David Cunningham,Kim Linton,Catherine Thieblemont,E. van den Neste,Umberto Vitolo,Julia Grunert,Marius Giurescu,Silvia Mappa,Barrett H. Childs,Franck Morschhauser +13 more
1
Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes
Alberto J. Arribas,Andrea Rinaldi,Ivo Kwee,Afua Adjeiwaa Mensah,Luciano Cascione,Jose A. Martinez-Climent,David Oscier,Luca Arcaini,Luca Baldini,Roberto Marasca,Catherine Thieblemont,Jean Soulier,Francesco Forconi,Alberto Zamò,Massimiliano Bonifacio,Manuela Mollejo,Fabio Facchetti,Stephan Dirnhofer,Maurilio Ponzoni,Govind Bhagat,Miguel A. Piris,Gianluca Gaidano,Emanuele Zucca,Davide Rossi +23 more
TL;DR: This report reports genome-wide DNA promoter methylation profiling of 137 SMZL samples with its clinical and biologic implications and confirmed the prognostic relevance of the High-M phenotype.
1
The NF-κB Pathway Is Targeted by Multiple Genetic Lesions In Splenic Marginal Zone Lymphoma
Davide Rossi,Daniela Capello,Silvia Rasi,Valeria Spina,Marco Fangazio,Riccardo Bruna,Silvia Franceschetti,Stefania Cresta,Luca Arcaini,Luca Baldini,Jean Soulier,Catherine Thieblemont,Roberto Marasca,Fabio Facchetti,Andrea Rinaldi,Francesco Bertoni,Gianluca Gaidano +16 more
TL;DR: SMZL was characterized by an array of lesions affecting genes at different levels of the NF-kB pathway, including TNFAIP3 , TRAF3 , BIRC3 and CD79A, which carried somatic mutations in genes regulating the NF -kB pathway.
1